Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase

https://doi.org/10.1016/0022-510X(72)90021-4Get rights and content

Abstract

Levodopa has been administered to Parkinsonian patients with and without an extracerebral decarboxylase inhibitor. Dyskinesia was the commonest dose-limiting factor on both regimens. For each individual patient dyskinesia occurred at the same plasma concentration of levodopa. In view of this “within-patient” correlation between dyskinesia and the plasma concentration of levodopa, attempts to improve therapeutic results by augmenting the plasma levodopa are unlikely to be successful except in those patients with severe gastrointestinal side-effects.

References (28)

  • C. Clark et al.

    Attenuation of the vomiting response to L-dopa after decarboxylase inhibition

  • J. Constantinidis et al.

    Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain

    Experientia (Basel)

    (1968)
  • G.C. Cotzias et al.

    Modification of Parkinsonism: Chronic treatment with L-dopa

    New. Engl. J. Med.

    (1969)
  • D.L. Dunner et al.

    Plasma dopa response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

    Clin. Pharmacol. exp. Ther.

    (1971)
  • Cited by (20)

    • L|-DOPA Effect on Blood Pressure in Man

      1977, Progress in Brain Research
    View all citing articles on Scopus

    This work was supported by the Wellcome Trust and the Medical Research Council.

    View full text